Adenomatous Polyp, Crohn Disease, Familial Adenomatous Polyposis, Hereditary Intestinal Polyposis Syndrome, Recurrent Colon Cancer, Stage I Colon Cancer, Stage IIA Colon Cancer, Stage IIB Colon Cancer, Stage IIC Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer
Conditions
Keywords
Colorectal Disease, SILS, colorectal surgery
Brief summary
This study is being done to evaluate single incision laparoscopic surgery (SILS) for colorectal diseases, compared to multi-port laparoscopic surgery. This study is also intended to standardize the SILS technique for colorectal diseases
Detailed description
PRIMARY OBJECTIVES: I. To report the experience of SILS procedure in the treatment of colorectal disease. II. To standardize the SILS technique. OUTLINE: Patients undergo single incision laparoscopic surgery with GelPort® attachment. After completion of study treatment, patients are followed up at 2 weeks, 3 and 6 months, and at 1 year.
Interventions
PROCEDUREtherapeutic laparoscopic surgery
Undergo single incision laparoscopic surgery
Sponsors
Ohio State University Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients who are willing to give consent and comply with the evaluation and the treatment schedule * Patients with disease processes limited to the right colon; this will include Crohn's disease, polyp disease, and cancers of the right colon * American Society of Anesthesiologists (ASA) =\< 3
Exclusion criteria
* Inability to obtain informed consent * Previous right colon surgery * Previous extensive abdominal surgery that would limit the laparoscopic approach * Stage IV disease at surgery * Metastatic disease diagnosed by computed tomography (CT), magnetic resonance imaging (MRI), or nuclear imaging * Patient enrolled in other interventional study * ASA score greater than 3 * Any condition which precludes compliance with the study (Investigator discretion) * Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or that could impact the scientific integrity of the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Oncologic sample including size of specimen removed, number of lymph nodes (LN) removed, pathological type and staging, lymph node, vessel or perineural invasion, and status of margins | Up to 1 year | Summarized using descriptive statistics (i.e. means, standard deviations, 95% confidence intervals for continuous variables, and frequencies for discrete data). |
| Operative time | Up to 1 year | Summarized using descriptive statistics (i.e. means, standard deviations, 95% confidence intervals for continuous variables, and frequencies for discrete data). |
| Length of skin and fascial incisions | Up to 1 year | Summarized using descriptive statistics (i.e. means, standard deviations, 95% confidence intervals for continuous variables, and frequencies for discrete data). |
| Estimated blood loss | Up to 1 year | Summarized using descriptive statistics (i.e. means, standard deviations, 95% confidence intervals for continuous variables, and frequencies for discrete data). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life measured using the short form (SF)-12 health related quality of life scale (HQRL) scored using quality metric licensed software | Baseline | Linear mixed model will be applied with repeated measures considering the observations from the same patient are correlated. |
| Quality of life measured using the SF-12 HQRL scored using quality metric licensed software | 2 weeks | Linear mixed model will be applied with repeated measures considering the observations from the same patient are correlated. |
| Visual analogue pain scale scored on the scale from 0 to 10 where 0 is no pain, and 10 is the maximum pain | Baseline | Linear mixed model will be applied with repeated measures considering the observations from the same patient are correlated. |
| Visual analogue cosmesis scale scored on the scale from 0 to 10 where 0 is worst scar, and 10 is the best scar | 2 weeks | Linear mixed model will be applied with repeated measures considering the observations from the same patient are correlated. |
Countries
United States
Outcome results
None listed